SCHEMBL4416010

SCHEMBL4416010

Clc1[c]c(-c2ccc(Cl)s2)c(Cl)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.40
HSD17B1 P14061 5/20 0.33
HSD17B2 P37059 4/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM1A O60341 1/20 0.33
KDM4E B2RXH2 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
PPARG P37231 1/20 0.31
NCOA2 Q15596 1/20 0.31
NCOA1 Q15788 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9193008 0.71 CYP2A6 (0.50) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL144429 0.64 CYP2A6 (0.45) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL4463309 0.63 CYP2A6 (0.33) CYP2A6HSD17B1HSD17B2
SCHEMBL15287265 0.62 CYP2A6 (0.36) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL21777333 0.61 HSD17B1 (0.43) CYP2A6HSD17B1HSD17B2KDM4EPDGFRB
SCHEMBL679889 0.61 ALDH1A1 (0.40) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL1638687 0.60 CYP2A6 (0.38) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL5536652 0.60 CYP2A6 (0.37) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL19677275 0.60 KDM4E (0.40) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1
SCHEMBL5727958 0.60 HSD17B1 (0.38) CYP2A6HSD17B1HSD17B2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592387-A4 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS ELAN PHARM INC (US) 2009-05-06 EP disclosed
EP-1592387-A2 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS Elan Pharmaceuticals, Inc. (US) 2005-11-09 EP disclosed
WO-2004066932-A2 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS ELAN PHARMACEUTICALS INC. (US) 2004-08-12 WO disclosed